Artiva Biotherapeutics awarded RA Capital Management 16,250 derivative securities on 2026-09-10. The transaction represented 100.0% of RA Capital Management’s resulting derivative securities holding in Artiva, giving investors a precise view of the insider’s post-transaction position and the instrument involved.

Key Highlights

  • The transaction was recorded on 10 September 2026.
  • The transaction used SEC code A, identifying an award or grant.
  • RA Capital Management owned 16,250 derivative securities after the transaction.

Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) recorded an insider award of 16,250 derivative securities to RA Capital Management, L.P. The transaction left RA Capital Management holding 100.0% of its resulting derivative securities position in Artiva.

RA Capital Award Covers Resulting Derivative Holding

RA Capital Management, L.P. is identified as an insider of Artiva Biotherapeutics. The award took place on 10 September 2026 and involved 16,250 derivative securities. After the transaction, RA Capital Management owned 16,250 derivative securities of Artiva Biotherapeutics. That transaction represented about 100.0% of the insider’s resulting derivative securities holding.